Ruling threatens to upend patents on Moderna’s Covid-19 vaccine
Analysts said the decision opens the door to a protracted controversy and debate around the implications of the patent claims.
Related Articles
UnitedHealth’s Campaign to Quiet Critics
The company has invoked the murder of an executive last year to complain about coverage in news outlets, on streaming services and on social media.
UnitedHealth’s Campaign to Quiet Critics
The company has invoked the murder of an executive last year to complain about coverage in news outlets, on streaming services and on social media.
Is the One Big Beautiful Bill a Masterstroke—or a Disaster?
We asked Newt Gingrich, Larry Summers, Tyler Cowen, Jason Furman, and others what they think of the Republicans’ megabill.
FDA rejects Capricor’s cell therapy for Duchenne muscular dystrophy
The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment continues.
Just How Harmful Is Vaping? More Evidence Is Emerging.
A new study that found high levels of heavy metals in popular nicotine vapes adds to concerns about the products.
Justice Dept. Demands Private Patient Info From Trans Youth Medicine Providers
Doctors and hospitals were subpoenaed for private information on gender-related care for minors, the latest move by the Trump administration to stop the treatments.
Just How Harmful Is Vaping? More Evidence Is Emerging.
A new study that found high levels of heavy metals in popular nicotine vapes adds to concerns about the products.
FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no…
FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility
Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S. that will no…
FDA publishes rejection letters sent to drugmakers, with a big caveat
The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.